Home
NewsNewsWith ART Fertility Clinics now part of its network, IVI RMA Global has created a Middle East operating region to meet growing fertility needs. The integration boosts treatment capacity, scientific output, and care consistency across the UAE and Saudi Arabia as demographic pressures shape demand for assisted reproduction
IVI RMA Global has named the Middle East as its newest operating region after acquiring ART Fertility Clinics, a move that marks an important step in the IVI RMA Global expansion into fast-growing reproductive markets. The integration covers ART Fertility’s established operations in the UAE and its planned entry into Saudi Arabia, extending the company’s network beyond North America, Italy, Northern Europe, Iberia, Latam, and Czechia. Led by CEO Suresh Soni and Medical Director Dr. Human M. Fatemi, the move positions the combined platform to serve tens of thousands of patients across the region.
The expansion comes as the Middle East faces declining fertility rates, with World Bank data showing the UAE at 1.2 births per woman and continued declines in Saudi Arabia. Dr. Fatemi said, “Across the Middle East, there is a growing awareness of the importance of addressing fertility challenges directly, and we are seeing more individuals and couples seeking advanced solutions every day,” adding that ART Fertility’s integration will accelerate scientific progress and raise care standards. The acquisition strengthens the IVI RMA Global expansion strategy by bringing more than 300 clinicians, embryologists, and geneticists into its network, supported by proprietary research and protocols that have delivered pregnancy rates as high as 71% across multiple age groups.
Soni noted, “The entire ART Fertility team is excited about this combination of two leaders in global fertility meeting the fertility challenge in the Middle East,” highlighting opportunities to deepen clinical value and research output. ART Fertility’s scientific footprint stretches across major R&D investments, more than 268 peer-reviewed papers, 35 ongoing studies, and 11 conferences. Together, these efforts have helped cement its role as a reference point in reproductive medicine. These capabilities align with the broader IVI RMA Global expansion effort aimed at advancing fertility science and strengthening clinical practice across the region.
Javier Sánchez Prieto, CEO of IVI RMA Global, said, “We are always looking for quality organizations that meet our high standards and whose own success can strengthen our work,” emphasizing the expectation that demand for fertility care in the Middle East will continue to grow. The acquisition places IVI RMA in a strong position to lead scientific and clinical advancements throughout the region.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
INVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
Carea has launched its Trying to Conceive - IVF/IUI mode to help women undergoing intricate fertility treatment with risks of inconsistent clinic continuity through continuous tracking and expert guidance.
The Minnesota bill for infertility treatments mandates comprehensive insurance coverage for diagnosis, IVF, and fertility preservation across public and private health plans. Set for implementation in 2027, the legislation expands access, modernises infertility definitions, and ensures cost-sharing protections to make reproductive healthcare more equitable.
